Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,147 Cr
Revenue (TTM)
₹231 Cr
Net Profit (TTM)
₹25 Cr
ROE
6.5 %
ROCE
8.4 %
P/E Ratio
45.5
P/B Ratio
3.7
Industry P/E
26.42
EV/EBITDA
20.1
Div. Yield
0 %
Debt to Equity
0.3
Book Value
₹140.9
EPS
₹11.4
Face value
10
Shares outstanding
22,249,910
CFO
₹200.76 Cr
EBITDA
₹240.80 Cr
Net Profit
₹93.63 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sakar Healthcare
| 25.9 | 4.2 | 26.6 | 119.5 | 37.0 | 34.9 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sakar Healthcare
| 35.7 | -27.6 | 78.4 | 37.9 | 65.6 | 48.3 | 10.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sakar Healthcare
|
515.3 | 1,146.5 | 230.9 | 25.2 | 15.3 | 8.6 | 45.5 | 3.7 |
| 2,791.2 | 34,954.5 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.5 | 7.6 | |
| 7,827.5 | 19,500.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.1 | 23.4 | |
| 1,565.8 | 11,962.0 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.5 | 3.6 | |
| 1,499.2 | 9,174.0 | 1,196.4 | 149.4 | -- | 27.5 | 61.4 | 13.1 | |
| 1,332.1 | 18,306.4 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.4 | 5.1 | |
| 1,961.1 | 31,488.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.8 | 7.9 | |
| 4,887.1 | 22,230.2 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26 | 5.6 | |
| 4,778.6 | 7,957.7 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.1 | 11.4 | |
| 971.2 | 8,875.8 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.4 | 3.0 |
Micro caps with a bullish sentiment
3 min read•By Danish Khanna and Udhayaprakash
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in... ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India. Read more
Incorporated
2004
Chairman
Sanjay S Shah
Managing Director
Sanjay S Shah
Headquarters
Ahmedabad Dist, Gujarat
Website
Looking for more details about Sakar Healthcare Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Announcements
View Announcements
The share price of Sakar Healthcare Ltd is ₹515.30 (NSE) as of 02-Apr-2026 IST. Sakar Healthcare Ltd has given a return of 36.95% in the last 3 years.
The P/E ratio of Sakar Healthcare Ltd is 45.46 times as on 02-Apr-2026, a 72 premium to its peers’ median range of 26.42 times.
The P/B ratio of Sakar Healthcare Ltd is 3.66 times as on 02-Apr-2026, a 18 discount to its peers’ median range of 4.48 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
26.55
|
1.64
|
|
2024
|
68.64
|
3.11
|
|
2023
|
29.94
|
2.20
|
|
2022
|
15.24
|
1.82
|
|
2021
|
16.54
|
1.79
|
The 52-week high and low of Sakar Healthcare Ltd are Rs 577.95 and Rs 220.41 as of 02-Apr-2026.
Sakar Healthcare Ltd has a market capitalisation of ₹ 1,147 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sakar Healthcare Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.35
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.